I
nsulin resistance and hyperinsulinemia have been correlated with hypertension, dyslipidemia, glucose intolerance, and obesity, [1] [2] [3] as well as with atherosclerosis, cardiac hypertrophy, 4 ischemic heart disease, 5 and cerebrovascular disease. 6 The mechanisms responsible for the increased cardiovascular risk associated with insulin are not completely understood. Insulin has indirect effects on the cardiovascular system through increased renal sodium reabsorption, 7 enhanced sympathetic nervous system activity, 8 and direct actions on blood vessels modulating vascular tone. 7 The mechanisms of the action of insulin on vascular tone include alterations in nitric oxide 9 and cytosolic calcium. 10 The growth effects of insulin may be the most important factor in increased cardiovascular risk. 11, 12 Different forms of insulin such as insulin-like growth factor-I (IGF-I) 12 and proinsulin 13 participate along with insulin to stimulate vascular growth and atherosclerosis. 11 It also has been established that increased activity of the renin-angiotensin system (RAS) is associated with increased cardiovascular risk, including myocardial infarction. 14 Thus, it is possible that an interaction between insulin and the RAS may account for many high-risk cardiac conditions. However, the combined effects of insulin and the RAS on vascular function have not been fully evaluated. Clinically, blockade of the RAS with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin type 1 receptor (AT 1 -R) antagonists improves insulin action. 15, 16 The opposite effect (ie, whether insulin can modulate components of the RAS) has only been partially evaluated. A study in diabetic animals showed that renin release is increased by insulin and IGF-I. 17 In addition, blockade of the RAS by ACEI 18, 19 or AT 1 -R antagonists 20 prevents progression of atherosclerosis in various animal models. This effect of blockade of the RAS in prevention of cardiovascular complications is now being investigated in clinical trials. 21 These observations point to an interaction between insulin and the RAS in the control of vascular tone and growth. The action of insulin on blood vessels, especially its effects on cell growth, may be mediated through activation of the RAS.
The effect of insulin on vascular growth could be mediated through the tissue RAS. 22, 23 This study examines the effects of insulin on angiotensinogen and renin expression and production in cultured rat vascular smooth muscle cells (VSMCs). The effects of both insulin and angiotensin II (Ang II) on cell proliferation are also examined.
Methods

Cell Culture
VSMCs were isolated from rat thoracic aorta (male Sprague-Dawley rats, 250 to 300 g) by enzymatic dispersion 10, 24 and grown in a 1:1 mixture of Dulbecco's modified Eagle's medium and Ham's F-12 (Sigma Chemical Co) supplemented with 10% fetal calf serum (FCS, Tissue Culture Biologicals), 50 U/mL penicillin, and 50 g/mL streptomycin (Sigma). Confluent cultures were passaged after treatment with trypsin-EDTA and reseeding at a 1:4 ratio in fresh media. Cells (4 to 12 passages) were seeded into 100-mm (P100) culture dishes and reached confluence in 5 to 7 days. 10 Cell lines were randomly screened for smooth muscle actin expression by immunofluorescent staining with anti-rat smooth muscle actin (Enzo Diagnostics Inc) and fluorescence-conjugated rabbit anti-mouse IgG (Cappel Laboratories, Organon Teknica Corp).
Study Protocol
Confluent cells cultured in P100 dishes were deprived of serum for 24 hours before administration of insulin. Insulin (10 to 1000 U/mL, regular porcine insulin; U-100, Eli Lilly & Co) was then added. After 48 hours of insulin exposure, the media was collected for angiotensinogen and renin determinations, and RNA was extracted from the cells. Cell proliferation assays were performed in parallel. Confluent cells cultured in 12-well dishes (3512 Costar) were deprived of serum for 24 hours before stimulation with either insulin (10 to 10 000 U/mL) or Ang II (10 Ϫ10 to 10 Ϫ6 mol/L; Sigma) with or without RAS inhibition, which was via 3 doses of the ACEI captopril (1ϫ10 Ϫ7 , 1ϫ10
Ϫ7 mol/L). Doses of these drugs were determined according to previous reports in cultured VSMCs. 25, 26 After 48 hours, the growth rate of VSMCs was evaluated by pulse-labeled tritiated thymidine ([ 3 H]TdR) uptake as described below.
Detection of mRNA
Smooth muscle cell dishes were washed with Ca 2ϩ -Mg 2ϩ -free PBS lysed in 1 mL of 4 mol/L guanidine-isothiocyanate containing 25 mmol/L trisodium citrate (pH 7.0), 0.1 mol/L 2-mercaptoethanol, and 0.5% (wt/vol) n-lauroyl sarcosine. 27 The lysate was acidified with 0.1 volume of 2 mol/L sodium acetate, pH 4.0, then extracted by vigorous vortexing with an equal volume of extraction buffer, phenol:chloroform:isoamyl alcohol (50:50:1) containing 0.05% wt/ vol 8-hydroxyquinoline, saturated with 0.1 mol/L Tris, pH 8.0. This mixture was placed on ice for 20 minutes and then centrifuged at 10 000g for 20 minutes. The supernatant was collected, and the RNA was precipitated overnight from the aqueous phase by the addition of an equal volume of 2-propanol at Ϫ20°C. The precipitated RNA was collected by centrifugation (10 000g, 30 minutes), rinsed with 75% ethanol, and air-dried. Total RNA was quantified by absorbance at 260 nm and stored at Ϫ80°C until use. Messenger RNAs of angiotensinogen, 28 renin, 29 AT 1 -R, 30, 31 and GAPDH were quantified in the total RNA extract by RNA protection assay with [
32 P]CTPlabeled riboprobes. 32 Total RNA (1 g per slot) was denatured in 6ϫ SSC and 2.7 mol/L formaldehyde at 65°C and bound to a nitrocellulose filter (Optitran, BA-S 85, Schleister & Schuell) prewetted in 10ϫ SSC using a BRL Hybri-Slot Manifold (Life Technologies). The samples were washed through with 200 L of 10ϫ SSC, dried in a vacuum oven at 80°C for 2 hours, and stored at room temperature until assay. Blots were prehybridized at 45°C for 4 hours in buffer including 5ϫ SSPE, 50% formamide, 5ϫ Denhardt's solution, 50 g/mL denatured salmon sperm DNA, 0.5% SDS, and 1% PEG and then hybridized in the same buffer with 1 to 2ϫ10 6 cpm of probe at 45°C for 20 hours. Probes were synthesized to a complete rat angiotensinogen cDNA, 28 pRang-6, or to complete rat renin cDNA, 29 pRen-31, which had been cloned in pGEM-4 (Promega). A KpnI/EcoRI cDNA fragment that encodes for rat AT 1A -R mRNA was kindly provided by Dr Jeffrey K. Harrison (University of Florida, Gainesville, Fla). 31 GAPDH cDNA was purchased from Ambion Inc. After hybridization, the blots were washed with 0.1ϫ SSC, 0.1% SDS at 55°C for 20 minutes two times, and incubated in 2ϫ SSC, 20 g/mL RNase A for 15 minutes at room temperature to remove the unhybridized probe. Thereafter, the blots were washed again with 0.1ϫ SSC, 0.1% SDS, dried, and autoradiographed with UltraVision L (Sterling Diagnostic Imaging Inc) on a Dupont Cronex Lightning Plus intensifying screen for 5 to 7 days (Dupont-NEN).
For angiotensinogen and GAPDH mRNA expression, Northern blot hybridization was also performed. Electrophoresis in 1% agarose gel was performed with 20 g extracted mRNA in 1ϫ MOPS. Thereafter, mRNA was transferred from the gel to a nitrocellulose membrane in 20ϫ SSC. Hybridization and wash conditions were the same as for the slot blot hybridization. The developed autoradiographs were scanned with Personal Densitometer SI (Molecular Dynamics), and the peak heights of the resulting scans were used to quantify the amount of mRNA present in each sample using ImageQuant software (Molecular Dynamics). The signals obtained were corrected and normalized using the signals obtained for the GAPDH mRNA on quadruplicate blots.
Angiotensinogen and Renin in Culture Media
Angiotensinogen concentration in the culture media was quantified by radioimmunoassay determination of Ang I generated after incubation with homologous rat renin in the presence of angiotensinase inhibitors as described. 33, 34 Renin concentration in the culture media was measured by determination of the hourly rate of Ang I production in the presence of excess homologous renin-free angiotensinogen. 35 Samples were assayed for angiotensinogen and renin in triplicate. The limit of detection of generated Ang I for both angiotensinogen and renin determinations in these experiments is 50 pg/mL.
Cell Proliferation
The effect of captopril or losartan on insulin-mediated cell proliferation was estimated by assessing the rate of [ 3 H]TdR uptake during the final 4 hours of treatment. 36 [
3 H]TdR (1 Ci/mL, 3 mL per well, ICN Pharmaceuticals) was added to serum-free medium during the final 4 hours of incubation. After incubation, the medium was aspirated, and the cells were washed 3 times each in ice-cold PBS, 10% trichloroacetic acid, and then distilled water and allowed to air-dry. Cells were then solubilized in 1 mL 1% SDS, and the radioactivity of each sample was determined by liquid scintillation spectrometry using a Beckman LS-5801 spectrometer. The protein concentration of each sample was measured by the micro bicinchoninic acid method (Pierce) using an MRX plate reader (Dynatech Laboratories), and total protein was estimated by comparison of OD readings against known standards using the Biolinx protein analysis program (Dynatech Laboratories). Data are presented as [ 
Determination of Receptor on Insulin-Mediated Growth
To determine whether insulin-induced effects on growth were mediated by IGF-I receptor, [ 12 Cells in 12-well plates were grown to confluence and then rendered quiescent by incubation with serum-free medium for 24 hours. Insulin or IGF-I (Calbiochem; 1000 U/mL and 25 ng/mL, respectively) was added with or without ␣IR3 and incubated for 48 hours. [ 3 H]TdR uptake was determined as described above. 
Statistical Analysis
Results
Angiotensinogen, Renin and AT 1 -R Gene Expression in Insulin-Treated VSMCs Figure 1 , top, shows the autoradiograms for angiotensinogen, renin, and AT 1 -R mRNA expression in cultured VSMCs; Figure 1 , bottom, shows the densitometric analysis of the autoradiograms. Insulin treatment (1000 U/mL) increased angiotensinogen mRNA expression by 25-fold (arbitrary density units, PϽ0.05), whereas it had no effect on renin or AT 1 -R mRNA expression (Figure 1, top and bottom) . Northern blot analysis for insulin-stimulated angiotensinogen mRNA production in VSMCs showed a similar several-fold increase in angiotensinogen with insulin, with its signal set at approximately 18S 28 (data not shown).
Angiotensinogen and Renin Production in Insulin-Treated VSMCs
Addition of insulin from 10 to 1000 U/mL to the culture media produced a significant dose-dependent increase in angiotensinogen release by VSMCs (Figure 2 ). Renin levels were not detectable by this assay system with or without insulin exposure.
Effects of Insulin and Ang II on [ 3 H]Thymidine Uptake
There was a significant increase in [ 3 H]TdR uptake by VSMCs after 48 hours of incubation with insulin (100 to 10000 U/mL) compared with no insulin added (Figure 3 , top). Ang II (1ϫ10 Ϫ9 to 1ϫ10 Ϫ7 mol/L) also produced a significant dose-dependent increase in [ 3 H]TdR uptake in VSMCs compared with control ( Figure 3, bottom) . Experiments to elucidate the equivalent potencies of insulin and Ang II on VSMC proliferation revealed that 1000 U/mL insulin had effects similar to 4 to 6ϫ10 Ϫ10 mol/L Ang II (Table 1) 
Role of IGF-I Receptor in Insulin-Mediated Growth
Discussion
Both insulin resistance and hyperinsulinemia 5 and increased activation of the RAS 14 have been associated with hypertension, accelerated atherosclerosis, 4 and increased risk for cardiovascular events. However, the status of the RAS in insulin-resistant states and the effect of insulin on the RAS have not been examined in detail. Most reports describing a relationship between insulin and the RAS have been in whole animal models 37 describing systemic effects. Thus, Kobayashi et al 38 and Iyer et al 39 reported elevated levels of plasma Ang II in the insulin-resistant, hyperinsulinemic, fructose-fed rat model. These studies did not resolve whether the high insulin levels were the cause of the elevated plasma Ang II. Additionally, in diabetic animals, IGF-I has been shown to stimulate renin release. 17 The present study demonstrates in cultured VSMCs that insulin causes an increase in angiotensinogen mRNA transcription and augmentation of its production. Moreover, in a similar temporal fashion, insulin exposure increases VSMC growth, and this effect is partially abolished by ACE inhibition and AT 1 -R blockade. These data imply that insulin may participate in VSMC proliferation through the trophic effects of Ang II, an established growth factor in VSMCs. 40 The observation that the growth rate induced by 1000 U/mL insulin in VSMCs is similar to that induced by 4ϫ10 23 The presence of ACE activity is also suggested by these data and has been previously reported in vascular tissue. 42 Likewise, participation of the AT 1 -R in insulinmediated growth is implied by sensitivity to losartan, although AT 1 -R mRNA expression was not influenced by insulin treatment. Finally, the observation that in the absence of insulin, neither captopril nor losartan altered [
3 H]TdR uptake in VSMCs indicates a permissive role for insulin in growth mediated through the RAS.
Other investigators have described a role for the RAS in vascular growth. Makita et al 25 reported that losartan could block Ang II-mediated [
3 H]TdR uptake in human aortic smooth muscle cells. In other studies, insulin has been shown to alter AT 1 -R density in vascular tissue in fructose-fed rats. 39 Insulin-mediated effects on angiotensinogen mRNA expression have also been described in nonvascular tissue, specifically in Reuber H35 hepatoma cells. 43 In these studies, angiotensinogen mRNA expression was decreased by 24-hour insulin treatment, yet cell proliferation was increased. These findings indicate that the mechanism of insulinmediated cell growth may be tissue specific. 44 To justify the present findings, the transendothelial transport of insulin in the vasculature must be explained. Because specific high-affinity receptors for insulin are found in VSMCs, 45 transendothelial transport of insulin must take place. In fact, both receptor-and non-receptor-mediated insulin transport mechanisms have been described. Receptormediated transport of insulin across endothelial cells was described by King and Johnson, 46 and transendothelial insulin transport was described by Steil et al 47 to be insaturable. The high doses of insulin applied in these types of in vitro experiments in vascular tissue have also been questioned. Studies of insulin-stimulated growth and RAS expression included doses from 10 to 1000 U/mL. Although insulinstimulated growth was measurable at 10 U/mL, we did not observe significant stimulation of thymidine uptake at doses Ͻ100 U/mL of insulin. One possible explanation for this may be that the growth-stimulation pathway in our time course, 48 hours, may not involve the classic insulinstimulated growth pathways described in acute studies. Stimulation of the vascular RAS in the present experiments required a relatively high concentration of insulin, the system being activated only at doses Ͼ100 U/mL. The findings are in agreement with other reports using in vitro systems, in which high doses of insulin are needed to elicit a response. However, these observations also may reflect the condition noted in animal and human states of insulin resistance and hyperinsulinemia in which postmeal plasma insulin levels Ͼ100 U/mL are common. 48 The question of whether insulin-induced growth effects are mediated via the IGF-I receptor was examined in experiments performed in the presence of IGF-I receptor blockade. Both 1000 U/mL insulin and 25 ng/mL IGF-I stimulated [ 3 H]TdR uptake. Incubation with the anti-IGF-I receptor monoclonal antibody ␣IR3 significantly inhibited IGF-I-mediated [ 3 H]TdR uptake while having only a negligible effect on insulin-stimulated uptake. These data indicate that insulin-mediated effects occur as a result of stimulation of the insulin receptor and not the IGF-I receptor. Banskota et al 12 also found that IGF-I receptor blockade had little effect on insulin-mediated growth of cultured VSMCs at insulin concentrations Ͻ1000 U/mL.
Although these findings would imply that there is little insulin-mediated activation of the IGF-I receptor in VSMCs, alternative activation of the IGF-I pathway is possible. IGF-I is a potent growth factor, structurally similar to insulin, that can cross-react with the insulin receptor.
12, 49 Delafontaine et al 50 have shown that Ang II can increase IGF-I production in VSMCs. This study opens the possibility that IGF-I activation could also occur in VSMCs via insulin-mediated activation of the vascular RAS. In H35 hepatoma cells, 43 IGF-I and IGF-II do not alter angiotensinogen mRNA expression.
It is well known that insulin can affect regulation of gene transcription and production of several hormones and protooncogenes such as c-fos which promote cell growth. 51 Thus, it is possible that the mechanisms of insulin-stimulated RAS activation may be through mitogen-activated kinase cascades resulting in acceleration of angiotensinogen gene transcription. Growth factor-mediated production of intracellular hormones has also been previously reported. 52 Studies from our laboratory show that transcription of angiotensinogen and renin genes can be accelerated by Ang II via nuclear angiotensin receptor. 53 In conclusion, insulin increases cellular growth rate and induces production of tissue angiotensinogen in cultured rat VSMCs. Moreover, the effect of insulin is acute and operative both through the AT 1 -R and at the level of conversion of Ang I to Ang II. This finding suggests that hyperinsulinemia may contribute to vascular hypertrophy via activation of the vascular RAS, increasing angiotensinogen production and intracellular Ang II, and activation of the AT 1 -R. These studies indicate that inhibition of the vascular RAS by ACEI or AT 1 -R antagonists could diminish the progression of atherosclerosis in insulin-resistance states.
